ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by American Century Companies Inc.

American Century Companies Inc. cut its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 15.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,054,317 shares of the biotechnology company’s stock after selling 1,074,194 shares during the quarter. American Century Companies Inc. owned 2.61% of ADMA Biologics worth $67,687,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Quest Partners LLC acquired a new stake in shares of ADMA Biologics during the second quarter worth $29,000. EntryPoint Capital LLC acquired a new stake in ADMA Biologics in the first quarter valued at $31,000. CWM LLC lifted its holdings in ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after acquiring an additional 4,367 shares during the period. Acadian Asset Management LLC acquired a new stake in ADMA Biologics in the second quarter valued at $93,000. Finally, Simplicity Wealth LLC acquired a new stake in ADMA Biologics in the first quarter valued at $68,000. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Trading Up 2.5 %

NASDAQ:ADMA opened at $18.09 on Monday. The company has a market capitalization of $4.22 billion, a PE ratio of -904.50 and a beta of 0.61. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. ADMA Biologics, Inc. has a 52-week low of $3.06 and a 52-week high of $19.34. The stock has a fifty day simple moving average of $15.07 and a 200-day simple moving average of $10.52.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.02) EPS. On average, equities research analysts expect that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares in the company, valued at approximately $4,408,712.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares in the company, valued at approximately $4,408,712.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $16.90, for a total value of $408,135.00. Following the sale, the chief operating officer now owns 449,088 shares of the company’s stock, valued at approximately $7,589,587.20. The disclosure for this sale can be found here. Insiders sold 466,900 shares of company stock worth $8,224,121 in the last 90 days. 3.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ADMA has been the subject of a number of recent analyst reports. Cantor Fitzgerald raised their target price on ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Mizuho raised their target price on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, June 20th. Finally, HC Wainwright raised their target price on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a report on Monday, August 12th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ADMA Biologics presently has an average rating of “Buy” and an average price target of $15.50.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.